Green light for AbbVie’s Crohn’s disease therapy Rinvoq
MHRA approval for Rinvoq which treats adults with moderate to severely active Crohn’s Disease
Read More
Tag: Crohn’s
Subcutaneous Entyvio hits Crohn’s primary endpoint, misses secondary
If approved, the drug could have huge benefits for patients as they could self-administer their therapy from home.
Read More
IBD research smashes recruitment target two years early
In the UK, at least 300,000 people are affected by Crohn’s disease or ulcerative colitis.
Read More
EMA recommends new methotrexate measures
The Pharmacovigilance Risk Assessment Committee initially recommended new measures in July.
Read More
Janssen launches PhII/III programme testing Tremfya in Crohn’s
Janssen has kicked off a Phase II/III programme assessing Tremfya in Crohn’s Disease.
Read More
EU clears first allogeneic stem cell therapy
TiGenix and Takeda’s Alofisel has become the first allogeneic stem cell therapy to be approved for use across the European Union.
Read More
Shire’s SHP647 bags another orphan badge
US regulators have awarded orphan drug status to Shire’s investigational therapy, SHP647, for the treatment of paediatric patients with moderately to severely active Crohn’s disease.
Read More
New analysis backs use of Takeda’s Entyvio
Takeda has presented data from a post-hoc analysis showing signs of early symptomatic improvement in patients with ulcerative colitis or Crohn’s disease taking Entyvio.
Read More
NICE backs new option for Crohn’s disease
The National Institute for Health and Care Excellence is backing the use of Janssen’s biologic Stelara to treat adult patients with moderately to severely active Crohn’s disease.
Read More
AbbVie’s risankizumab bags Orphan status for paediatric Crohn’s
An experimental therapy being developed by AbbVie for paediatric patients with Crohn’s disease has been awarded Orphan Drug status in the US.
Read More
Janssen’s Stelara cleared to treat Crohn’s disease
Certain patients with Crohn’s disease have gained the potential to access a new treatment option in Europe with the expanded approval of Janssen’s psoriasis blockbuster Stelara.
Read More
Allergan picks up AZ’ Crohn’s drug in $1.52bn deal
AstraZeneca’s biologics research and development arm MedImmune has signed over global rights to its experimental Crohn’s disease drug MEDI2070 to Allergan, in a deal potentially worth $1.52 billion.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
